Skip to content
synovial sarcoma foundation
  • About
    • Mission
    • Initiatives
    • Affiliations
    • Leadership
    • Board of Directors
    • Medical Advisory Board
    • Careers
  • Resources
    • Synovial Sarcoma FAQ
    • Treatments
    • Clinical Trials & Therapies
    • Synovial Sarcoma Patient Survey
    • Synovial Sarcoma Tumor Board
    • Patient Stories
    • Patient Resources
    • Eddie’s Story
    • Video Resources
    • SSF Ambassador Program
  • Research Programs
    • Clinical Research
    • Tumor Glow
    • Synovial Sarcoma Registry
  • Latest News
Donate

Send us a note

Please fill out the form below and we will gladly respond as soon as possible.



    Research, Latest News

    New Market Insights Highlight Growth in Synovial Sarcoma Treatments

    September 10, 2025 joshs Comments Off on New Market Insights Highlight Growth in Synovial Sarcoma Treatments
    A doctor in a white coat with a stethoscope around their neck holds a digital tablet, standing near a window. Only the upper body is visible. Another hand is blurred in the foreground.

    The Synovial Sarcoma Foundation is committed to staying informed on the latest research and developments in this rare and aggressive cancer. A recent market report indicates that the global synovial sarcoma market is projected to grow significantly, reaching an estimated USD 420 million by 2034 — up from USD 245 million in 2024, at a compound annual growth rate (CAGR) of 6.8%.

    Key growth drivers include increasing incidence rates worldwide, especially among younger populations, alongside expanding clinical pipelines of innovative treatments such as immunotherapies and targeted agents. The industry also benefits from a global shift toward rare disease research, with increased investments in orphan drugs and cutting-edge clinical trials.

    Leading pharmaceutical companies like Bayer, Roche, GSK, Pfizer, US WorldMeds, and several biotech firms are actively advancing research into therapies that harness the immune system and target specific tumor markers. One notable example is Afamitresgene autoleucel (Afami-cel), a T-cell receptor therapy initially developed by Adaptimmune. Adaptimmune has driven a significant share of recent investment into synovial sarcoma research, and Afami-cel was recently acquired by US WorldMeds. Alongside Afami-cel, US WorldMeds also acquired other T-cell therapies in development that could impact synovial sarcoma treatment, including Lete-cel and Uza-cel, expanding the scope of potential options for patients.

    While traditional chemotherapy remains a mainstay, the future is increasingly focused on biologics, cell and gene therapies, and biomarker-driven diagnostics. Healthcare providers, research institutes, and specialty cancer centers are vital in delivering current treatments and conducting innovative clinical research.

    The Synovial Sarcoma Foundation continues to advocate for research, patient support, and awareness as the field evolves. We are dedicated to ensuring that patients and families affected by synovial sarcoma have access to the latest information and emerging therapies.

    For more detailed insights, visit the original market report: [Link to the source article].

    Sources: OpenPR, Market Research Reports

    • awareness
    • biotech advancements
    • patient support
    • Rare Cancer
    • research
    • Synovial Sarcoma Foundation
    joshs

    Post navigation

    Previous
    Next

    Search

    Categories

    • Black Flag Racing (2)
    • Case Study (5)
    • Children (1)
    • CHOP (3)
    • Clinical Trial (4)
    • Development (12)
    • Dr. Theodore Laetsch (3)
    • Education (27)
    • Europe Expansion (1)
    • Healthcare (13)
    • Latest News (22)
    • Patient Story (1)
    • Programs (1)
    • Rare Cancer (7)
    • Rare Cancer Funding (2)
    • Research (21)
    • SSF Ambassador Program (1)
    • Synovial Sarcoma Conference (2)
    • Synovial Sarcoma Registry (7)
    • Teresa Belluco (1)
    • Tumor Board (2)

    Recent posts

    • A doctor in a white coat with a stethoscope around their neck holds a tablet device, standing in a medical setting with a patient lying on a bed in the background.
      Synovial Sarcoma of the Tibial Nerve: A Case of Diagnostic Ambiguity and Limb Salvage
    • A scientist wearing blue gloves adjusts a microscope slide.
      Can We Reactivate T Cells After TCR-T Therapy Stops Working?
    • Hands wearing blue nitrile gloves draw liquid from a small glass vial into a syringe, with a rack of test tubes in the background.
      Why Every Tumor Sample Matters: What a New Sarcoma Biobank Study Means for Synovial Sarcoma

    Tags

    #AYACancer #CancerResearch #CaseReport #CellTherapy #ClinicalTrials #Immunotherapy #KnowYourOptions #MAGEA4 #MolecularDiagnostics #NYESO1 #PatientAdvocacy #RareCancer #RareDisease #Sarcoma #SarcomaAwareness #SoftTissueSarcoma #SS18SSX #SynovialSarcoma #SynovialSarcomaFoundation #TumorBoard Afami-cel Afamitresgene autoleucel Cancer Research CHOP immunotherapy MAGE-A4 synovial sarcoma NY-ESO-1 synovial sarcoma precision medicine Rare Cancer rare cancer research rare soft tissue sarcoma research sarcoma research sarcoma treatment soft tissue sarcoma Synovial Sarcoma synovial sarcoma biomarker testing synovial sarcoma diagnosis Synovial Sarcoma Foundation synovial sarcoma immunotherapy synovial sarcoma treatment T-Cell Therapy targeted therapy TCR Therapy TECELRA

    Related posts

    A scientist wearing blue gloves adjusts a microscope slide.
    Clinical Trial, Development

    Can We Reactivate T Cells After TCR-T Therapy Stops Working?

    November 3, 2026 ayushis Comments Off on Can We Reactivate T Cells After TCR-T Therapy Stops Working?

    A new pilot trial at Northwestern University is asking one of the most important questions in synovial sarcoma treatment: when TCR-T therapy stops working, are the T cells truly gone, or can they be brought back to life? Background: The Promise and the Limit of TCR-T Therapy TCR-T cell therapy represents a major advance for […]

    Hands wearing blue nitrile gloves draw liquid from a small glass vial into a syringe, with a rack of test tubes in the background.
    Latest News, Synovial Sarcoma Registry

    Why Every Tumor Sample Matters: What a New Sarcoma Biobank Study Means for Synovial Sarcoma

    October 28, 2026 ayushis Comments Off on Why Every Tumor Sample Matters: What a New Sarcoma Biobank Study Means for Synovial Sarcoma

    A new study in Advanced Science (October 12, 2026) shows what becomes possible when patients donate tumor tissue and researchers pair it with detailed clinical and genetic data. The same idea drives the Synovial Sarcoma Registry and Biorepository, and every patient who joins makes the next study possible. What the study found Over ten years, […]

    Close-up of blue gloved hands adjusting a microscope with two visible objective lenses, focusing on a glass slide in a laboratory setting.
    Education, Research

    The Cells Around the Tumor May Hold the Key to Improving Immunotherapy in Synovial Sarcoma

    September 14, 2026 ayushis Comments Off on The Cells Around the Tumor May Hold the Key to Improving Immunotherapy in Synovial Sarcoma

    A new study published in PLOS One by Ji-Yong Sung, Jin-Hong Kim, and Yi-Jun Kim from Seoul National University and Ewha Womans University, South Korea, examines a type of cell found in the tissue surrounding tumors, called cancer-associated fibroblasts (CAFs), and asks whether they can predict how a sarcoma patient will respond to immunotherapy. What […]

    The Synovial Sarcoma Foundation is a registered 501(c)(3) nonprofit organization. Tax ID number is 33-4027591. Contributions to the Synovial Sarcoma Foundation are tax-deductible to the extent permitted by law.

    • Terms & conditions
    • Privacy policy
    synovial sarcoma foundation
    • community@synovialsarcoma.org
    1025 Thomas Jefferson St. NW, Suite W-3200, Washington DC 20007
    Facebook-f X-twitter Linkedin

    Navigation

    • About
    • Research Programs
    • Patient Stories
    • Resources

    Stay in touch